Company news

Neuren Pharmaceuticals Limited news in 2025

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2025, newest first.

View company

FDA approves DAYBUE STIX (trofinetide), powder formulation

December 14, 2025

Record DAYBUE net sales of US$101.1 million in Q3 2025

November 5, 2025

Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid

October 19, 2025

Half Yearly Report and Accounts

August 26, 2025

First site initiated for Neuren's PMS Phase 3 trial

August 24, 2025

Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline

August 7, 2025

DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024

August 7, 2025

US patent allowed for NNZ-2591 to treat Pitt Hopkins

June 25, 2025

AGM Chair Address & CEO Presentation

May 27, 2025

DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024

May 7, 2025

NEU confirms primary endpoints for Phase 3 trial in PMS

April 13, 2025

Neuren initiates development of NNZ-2591 to treat HIE

March 26, 2025

Neuren receives DAYBUE sales milestone payment of US$50m

February 28, 2025

2024 results - A$166m comprehensive income for shareholders

February 27, 2025

Appendix 4E and 2024 full year accounts

February 27, 2025

DAYBUE (trofinetide) 2024 net sales US$348 million

February 26, 2025

Neuren receives Rare Pediatric Disease Designation from FDA

February 23, 2025

Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins

February 19, 2025

Priority Review Voucher sale proceeds received

February 7, 2025

Trofinetide marketing application submitted in Europe

January 14, 2025

Decks in 2025